{"id":45322,"date":"2025-10-30T22:08:21","date_gmt":"2025-10-30T14:08:21","guid":{"rendered":"https:\/\/flcube.com\/?p=45322"},"modified":"2025-10-30T22:08:22","modified_gmt":"2025-10-30T14:08:22","slug":"ascletis-launches-asc36-a-once%e2%80%91monthly-injectable-targeting-obesity","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45322","title":{"rendered":"Ascletis Launches ASC36, a Once\u2011Monthly Injectable Targeting Obesity"},"content":{"rendered":"\n

China\u2011based Ascletis Pharma Inc. (HKG: 1672<\/a>) announced the selection of ASC36, a once\u2011monthly subcutaneous injectable amylin\u2011receptor agonist, as its latest clinical development candidate. The company plans to file an Investigational New Drug (IND) application with the U.S. FDA for obesity indications in the second quarter of 2026.<\/p>\n\n\n\n

Technology\u2011Driven Design Enables Monthly Dosing<\/strong>
ASC36 was engineered through Ascletis\u2019 proprietary Artificial Intelligence\u2011Assisted Structure\u2011Based Drug Discovery (AISBDD) platform combined with its Ultra\u2011Long\u2011Acting Platform (ULAP). The result is a peptide with an extended apparent half\u2011life\u2014time to 50\u202f% Cmax\u2014plus superior per\u2011milligram bioavailability. These attributes permit once\u2011monthly, subcutaneous administration with a volume not exceeding 1\u202fmL, offering a patient\u2011friendly dosing schedule that could reshape obesity therapy.<\/p>\n\n\n\n

Manufacturing Scalability and Cost Advantage<\/strong>
Optimized design characteristics translate directly into manufacturing efficiencies. Because the peptide\u2019s dosing volume is low and its pharmacokinetic profile stable, Ascletis anticipates reduced production costs compared with daily\u2011dosed analogs. The company\u2019s streamlined synthetic route and scalable bioprocess further strengthen its commercial advantage, positioning ASC36 as a potentially best\u2011in\u2011class candidate within the obesity market.<\/p>\n\n\n\n

Strategic Implications for Ascletis and the Market<\/strong>
The introduction of ASC36 aligns with Ascletis\u2019s strategy to expand its therapeutic portfolio beyond oncology, leveraging its AI\u2011driven discovery capabilities. If the IND is approved and subsequent trials demonstrate efficacy, ASC36 could capture a significant share of the rapidly growing global obesity drug market, estimated to exceed $100\u202fbillion by 2030. Market analysts note that a once\u2011monthly dosing schedule may enhance patient adherence, a critical factor in obesity management.<\/p>\n\n\n\n

Investor Outlook<\/strong>
Ascletis\u2019s clinical\u2011development milestone should be followed closely by investors. Key performance metrics\u2014including IND submission timing, Phase\u202fI PK\/PD results, and safety profile\u2014will provide early signals of therapeutic feasibility. The company\u2019s cost\u2011efficient production model and strong AI infrastructure add value beyond immediate pipeline prospects, potentially driving long\u2011term valuation upside for Ascletis shareholders.-Fineline Info & Tech<\/a><\/p>\n\n\n\n